Worldwide Study Finder

Loading registry information…

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:54 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

GLP-1 Effects on Insulin and Glucagon in PTDM

ClinicalTrials.gov · NCT02591849 · Registry updated: 2016-03-31

Condition / research focus: Post-transplant Diabetes Mellitus
Sponsor: Oslo University Hospital
Countries with listed sites: Norway
Registry dates and results: Start: 2014-10. Completion: 2015-03 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-like peptide-1 (GLP-1) (dietary_supplement)
Isotonic saline (other)
Hyperglycemic clamp (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Oslo University Hospital, Rikshospitalet
Oslo, Oslo, Norway
Site recruitment: Not reported

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Phase not reported / not applicableCompletedOBSERVATIONAL

Incretin-based Drugs and Pancreatic Cancer

ClinicalTrials.gov · NCT02475499 · Registry updated: 2016-03-14

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Countries with listed sites: Canada
Registry dates and results: Start: 2014-03. Completion: 2015-04 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DPP-4 inhibitors (drug) — also listed as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin
GLP-1 analogs (drug) — also listed as: incretin-based drugs, exenatide, liraglutide
Sulfonylureas (drug) — also listed as: oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine
Biguanides (drug) — also listed as: oral hypoglycemic agent, phenformin, metformin, buformin
Thiazolidinediones (drug) — also listed as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
Alpha-glucosidase inhibitors (drug) — also listed as: oral hypoglycemic agent, acarbose, miglitol, voglibose
Meglitinides (drug) — also listed as: oral hypoglycemic agent, repaglinide, nateglinide

Where the study takes place — 1 listed sites

Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Worldwide Study Finder

Find a study

Registry search results

GLP-1 Effects on Insulin and Glucagon in PTDM

Explore the world’s study registries

Worldwide

Africa

Americas

Physiologic Response to Glucagon at Varying Insulin Levels

A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

Incretin-based Drugs and Pancreatic Cancer

Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Short Bowel Syndrome and Teduglutide Versus Placebo

Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Liraglutide in Type 1 Diabetes

Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

Effects of GLP-1 on Chronic Heart Failure

Asia

Middle East

Europe

Oceania